Formoterol
- Generic Name
- Formoterol
- Brand Names
- Bevespi, Breyna, Breztri, Duaklir, Duaklir Genuair, Dulera, Foradil, Oxeze, Perforomist, Symbicort, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O4
- CAS Number
- 73573-87-2
- Unique Ingredient Identifier
- 5ZZ84GCW8B
- Background
Formoterol is an inhaled beta-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled ...
- Indication
Formoterol is indicated in various formulations for the treatment of asthma and COPD. For the treatment of COPD, formoterol is available as a single-entity inhalation solution, in combination with the long-acting muscarinic antagonists (LAMAs) aclidinium and glycopyrronium, and in combination with the corticosteroid budesonide. For the treatment of asthma, f...
- Associated Conditions
- Asthma, Bronchial Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Associated Therapies
- Maintenance therapy
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Conditions
- Interventions
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 841
- Registration Number
- NCT00909779
- Locations
- ๐บ๐ธ
C.A.R.E. Clinical Research, St. Louis, Missouri, United States
๐บ๐ธNeem Research Group, Inc., Columbia, South Carolina, United States
๐บ๐ธDCT, Sugar Land, Texas, United States
Rapid Onset Action of Salbutamol Versus Formoterol
- First Posted Date
- 2009-05-13
- Last Posted Date
- 2009-05-13
- Target Recruit Count
- 78
- Registration Number
- NCT00900874
- Locations
- ๐ฎ๐ณ
AIIMS, New Delhi, India
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
- Conditions
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 217
- Registration Number
- NCT00812682
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 937
- Registration Number
- NCT00796653
- Locations
- ๐จ๐ฆ
1222.14.4007 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada
๐ฉ๐ช1222.14.4103 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
๐ฎ๐น1222.14.4301 Boehringer Ingelheim Investigational Site, Cassano Delle Murge (ba), Italy
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
- Conditions
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 906
- Registration Number
- NCT00793624
- Locations
- ๐ซ๐ฎ
1222.13.2101 Boehringer Ingelheim Investigational Site, Tampere, Finland
๐ฒ๐พ1222.13.3102 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia
๐ซ๐ฎ1222.13.2102 Boehringer Ingelheim Investigational Site, Turku, Finland
Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 54
- Registration Number
- NCT00742248
- Locations
- ๐ฎ๐น
"Centro Dipartimentale di Fisiopatologia Respiratoria", University of Genoa, Genova, Italy
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 37
- Registration Number
- NCT00736489
- Locations
- ๐ธ๐ช
Research Site, Lund, Sweden
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 255
- Registration Number
- NCT00706446
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
- Conditions
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- University of New Mexico
- Registration Number
- NCT00662779
- Locations
- ๐บ๐ธ
University of New Mexico, Albuquerque, New Mexico, United States
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT00658255
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.